FORSTEO ( DrugBank: - )


3 diseases
IDDisease name (Link within this page)Number of trials
70Spinal stenosis2
235Hypoparathyroidism2
274Osteogenesis Imperfecta1

70. Spinal stenosis


Clinical trials : 96 Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-006152-36-DK
(EUCTR)
10/05/201210/05/2012Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing?Postoperative treatment with parathyroidea hormone Forteo® inpatients undergoing posterolateral spinal fusion surgery. A prospektiveand a randomized double-blinded, placebo-controlled study - PTH-U-DESE-STUDY Spinal stenosis
MedDRA version: 14.1;Level: LLT;Classification code 10041597;Term: Spinal stenosis of lumbar region;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Forteo
Product Name: Forsteo
Product Code: 0002-8971
INN or Proposed INN: teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34)
Other descriptive name: rhPTH (1-34)
Middelfart RygsektorNULLNot RecruitingFemale: yes
Male: yes
100Phase 2Denmark
2EUCTR2011-002917-12-SE
(EUCTR)
06/12/201127/09/2011Does parathyroid hormone enhance healing after spinal fusion?Does PTH enhance healing after spinal fusion? - PTH spinal stenosis Decompression and fusion due to spinal stenosis in men and postmenopausal women. In this study we want to examine if Forsteo (teriparatide) improves bone healing (jugded by blinded investigators) and if this improves the function and decreases the pain at 7 weeks and 6 months.;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]Trade Name: ForsteoDepartment of Orthopaedics IKEDepartment of Orthopaedics IKENot RecruitingFemale: yes
Male: yes
100Phase 4Sweden

235. Hypoparathyroidism


Clinical trials : 88 Drugs : 128 - (DrugBank : 25) / Drug target genes : 5 - Drug target pathways : 7
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-000500-29-FR
(EUCTR)
03/06/201626/04/2016A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant HypocalcemiaA randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia - ACTICAS Autosomal dominant hypocalcemia (ADH)
MedDRA version: 19.0;Level: PT;Classification code 10021041;Term: Hypoparathyroidism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: FORSTEO-R
Product Name: FORSTEO-R
INN or Proposed INN: Tériparatide
Other descriptive name: FORSTEO-R
Trade Name: ESIDREX-R 25 mg
Product Name: ESIDREX-R 25 mg
INN or Proposed INN: Hydrochlorothiazide
Other descriptive name: ESIDREX-R
Trade Name: UN-ALPHA-R 0.25µg
Product Name: UN-ALPHA-R 0.25µg
INN or Proposed INN: Alfacalcidol
Other descriptive name: UN-ALPHA-R
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
25Phase 2France
2EUCTR2013-001890-26-IT
(EUCTR)
06/05/201427/03/2014Recombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidismRecombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidism Refractory hypoparathyroidism
MedDRA version: 16.1;Level: PT;Classification code 10021041;Term: Hypoparathyroidism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: FORSTEO
Product Name: FORSTEO
INN or Proposed INN: TERIPARATIDE
Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di FirenzeNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 3Italy

274. Osteogenesis Imperfecta


Clinical trials : 87 Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-002811-27-DK
(EUCTR)
07/11/201104/11/2011The Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis ImperfectaThe Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis Imperfecta - OI-treatment Osteogenesis imperfecta;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: Forsteo
Product Code: H05AA02
Trade Name: Aclasta
Bente Langdahl, consultant, ass. professor, PhD, DMScNULLNot RecruitingFemale: yes
Male: yes
80Phase 2Denmark